OSE Immunotherapeutics : and Boehringer Ingelheim expand collaboration to develop first in class treatments for cancer and cardio renal metabolic diseases
OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases Nantes,...
Source: marketscreener.com